At a glance

Type

Topical cosmetic ingredient

Regulatory context

The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.

Evidence

The studies below measured biological responses in cultured cells, excised skin or animals. They do not establish systemic treatment outcomes in people.

What it is

GHK is a three-amino-acid peptide that binds copper. The complex has been studied in connective-tissue biology and skin-care formulations. A chemical identity and a plausible biological mechanism are starting points for research, not proof of a rejuvenation treatment. [1]

What cell research shows

A 1988 fibroblast-culture study reported increased collagen synthesis after exposure to GHK-Cu. The experiment measured a cellular response, not visible skin change, wound closure or a patient-reported benefit in a clinical trial. [1]

What newer tissue research adds

A 2023 study tested GHK-Cu with hyaluronic acid in human dermal fibroblasts and an ex-vivo skin model. It measured collagen expression and found a combination effect under the tested conditions. Excised tissue is not a treated patient; the work does not establish the efficacy of other mixtures or injectable products. [2]

Why the delivery route matters

A separate microemulsion study examined a specific topical delivery system and hair-related responses in mice. Its formulation and model are integral to the result. It cannot establish human hair regrowth, and a topical-delivery finding cannot be converted into an injectable-use claim. [3]

What remains uncertain

Meaningful clinical questions include whether a precisely defined formulation changes a patient-relevant outcome, how large the effect is, how long it lasts and what adverse effects occur. The primary studies summarised here do not answer those questions for injected GHK-Cu. Nor can a study of GHK-Cu establish what an unnamed multi-ingredient blend does. [1] [2] [3]

Questions for your doctor

Is this a topical product or a proposed systemic preparation? What human evidence exists for the exact formulation and intended use? A catalogue name, laboratory mechanism and lot document answer different questions and should be reviewed separately. [4]

Safety and clinical context

FDA identifies limited human safety data and potential immunogenicity concerns for injectable GHK-Cu. Topical and injectable preparations require separate assessment. [4]

Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.